AR055283A1 - Inhibidores de cisteinproteasa de catepsina - Google Patents
Inhibidores de cisteinproteasa de catepsinaInfo
- Publication number
- AR055283A1 AR055283A1 ARP050104742A ARP050104742A AR055283A1 AR 055283 A1 AR055283 A1 AR 055283A1 AR P050104742 A ARP050104742 A AR P050104742A AR P050104742 A ARP050104742 A AR P050104742A AR 055283 A1 AR055283 A1 AR 055283A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halos
- inhibitors
- substituted
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere a una clase de compuestos que son inhibidores de la cisteinproteasa, incluyendo pero sin limitarse a estos, inhibidores de las catepsinas K, L, S y B. Estos compuestos son utiles para el tratamiento de enfermedades en las que está indicada la inhibicion de la resorcion osea, tal como la osteoporosis. Reivindicacion 1: Un compuesto de formula (1) en la que R1 y R2 se toman conjuntamente con el átomo de C al cual están unidos para formar un cicloalquilo C3-4 que está opcionalmente sustituido con alquilo C1-3; R3 es alquilo C1-6 que está sustituido con uno a cuatro fluoros o uno a cuatro cloros; R4 es alquilo C1-6 que está sustituido con uno a cinco halos; R5 es H o alquilo C1-6 que está sustituido con uno a cinco halos; cada D es independientemente arilo o heteroarilo; R6 es H o alquilo C1-6 que está opcionalmente sustituido con uno o dos hidroxilos o dos a seis halos; R7 es alquilo C1-6 que está opcionalmente sustituido con dos a cinco halos; n es dos; o una sal , estereoisomero o derivado de N-oxido farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63040504P | 2004-11-23 | 2004-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055283A1 true AR055283A1 (es) | 2007-08-15 |
Family
ID=36497694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104742A AR055283A1 (es) | 2004-11-23 | 2005-11-11 | Inhibidores de cisteinproteasa de catepsina |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20070293578A1 (es) |
| EP (1) | EP1817276B1 (es) |
| JP (1) | JP5055488B2 (es) |
| KR (1) | KR20070085435A (es) |
| CN (2) | CN101061093A (es) |
| AR (1) | AR055283A1 (es) |
| AU (1) | AU2005309267B2 (es) |
| BR (1) | BRPI0518054A (es) |
| CA (1) | CA2589085C (es) |
| DK (1) | DK1817276T3 (es) |
| ES (1) | ES2394618T3 (es) |
| IL (1) | IL183308A (es) |
| MX (1) | MX2007006136A (es) |
| MY (1) | MY137717A (es) |
| NO (1) | NO339125B1 (es) |
| NZ (1) | NZ554872A (es) |
| PE (1) | PE20061054A1 (es) |
| PL (1) | PL1817276T3 (es) |
| PT (1) | PT1817276E (es) |
| RU (1) | RU2399613C2 (es) |
| SI (1) | SI1817276T1 (es) |
| TW (1) | TWI353244B (es) |
| WO (1) | WO2006056047A1 (es) |
| ZA (1) | ZA200703530B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ534583A (en) * | 2002-03-05 | 2006-11-30 | Axys Pharm Inc | Leucinamide derivatives suitable as cathepsin cysteine protease inhibitors |
| WO2005028429A2 (en) * | 2003-09-18 | 2005-03-31 | Axys Pharmaceuticals, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
| JP4988589B2 (ja) * | 2004-12-01 | 2012-08-01 | ビロベイ，インコーポレイティド | システインプロテアーゼインヒビターとしてのハロアルキル含有化合物 |
| JP5154944B2 (ja) * | 2004-12-02 | 2013-02-27 | ビロベイ，インコーポレイティド | システインプロテアーゼインヒビターとしてのスルホンアミド含有化合物 |
| EP1841419A4 (en) * | 2005-01-19 | 2009-02-25 | Merck Frosst Canada Ltd | CATHEPSIN K AND ADIPOSITAS INHIBITORS |
| PT1855674E (pt) | 2005-03-02 | 2014-10-08 | Merck Canada Inc | Composição para a inibição de catepsina k |
| CA2602175C (en) * | 2005-03-21 | 2012-11-27 | Applera Corporation | Alpha ketoamide compounds as cysteine protease inhibitors |
| CA2602112A1 (en) * | 2005-03-22 | 2006-09-28 | Celera Genomics | Sulfonyl containing compounds as cysteine protease inhibitors |
| EP2077869B1 (en) * | 2006-08-28 | 2015-02-25 | Akademia Medyczna Im. Piastow Slaskich We Wroclaw iu | A system for the extra-corporeal purification of blood of pathogenic enzymes |
| EP2076490A4 (en) * | 2006-09-25 | 2010-07-28 | Merck Frosst Canada Ltd | INHIBITORS OF CATHEPSIN B |
| US7893112B2 (en) | 2006-10-04 | 2011-02-22 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
| KR101486763B1 (ko) * | 2006-10-04 | 2015-01-28 | 비로베이, 인코포레이티드 | 시스테인 프로테아제 억제제로서의 디플루오로 함유 화합물 |
| WO2009065098A1 (en) * | 2007-11-16 | 2009-05-22 | Velcura Therapeutics, Inc. | Use of cathepsin k antagonists in the treatment of bone cancer |
| CA2743749A1 (en) * | 2008-11-13 | 2010-05-20 | Virobay, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
| US8324417B2 (en) * | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
| WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| CN106916091B (zh) * | 2015-12-24 | 2020-10-09 | 广东东阳光药业有限公司 | 组织蛋白酶k抑制剂及其用途 |
| US10758559B1 (en) * | 2017-09-01 | 2020-09-01 | University Of Wyoming | Targeting cathepsin K to facilitate wound healing |
| US11766467B2 (en) | 2017-09-01 | 2023-09-26 | University Of Wyoming | Methods of treating wounds using cathepsin K inhibitors |
| CN112513008A (zh) | 2018-08-02 | 2021-03-16 | 英特维特国际股份有限公司 | 选择性组织蛋白酶半胱氨酸蛋白酶抑制剂的制备方法 |
| EP3830075A1 (en) * | 2018-08-02 | 2021-06-09 | Intervet International B.V. | Crystalline forms of n1-(1-cyanocycloproply)-n2-((1s)-1-{4'-[(1r-2,2-difluoro-1-hydroxyethyl]biphenyl-4-yl}-2,2,2-trifluoroethyl)-4-fluoro-l-leucinamide |
| WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| CN112438972B (zh) * | 2019-08-29 | 2021-07-30 | 沈阳药科大学 | 组织蛋白酶抑制剂的医药用途 |
| CN113462728B (zh) * | 2021-07-09 | 2024-06-07 | 浙江工业大学 | 一种利用土星轮头酵母制备(r)-1-(4-溴苯基)-2,2,2-三氟乙醇的方法 |
| CN116462570B (zh) * | 2023-03-14 | 2025-06-24 | 昆明理工大学 | 一种α-二氟甲基苯乙烯衍生物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9813197A (pt) * | 1997-11-05 | 2000-08-29 | Novartis Ag | Dipeptìdeo nitrilas |
| US7012075B2 (en) | 2001-03-02 | 2006-03-14 | Merck & Co., Inc. | Cathepsin cysteine protease inhibitors |
| US7302587B2 (en) * | 2001-06-08 | 2007-11-27 | Matra Transport International | Secure computer system |
| AU2002352663B2 (en) * | 2001-11-13 | 2007-06-21 | Axys Pharmaceuticals, Inc. | Cyanoalkylamino derivatives as protease inhibitors |
| NZ534583A (en) * | 2002-03-05 | 2006-11-30 | Axys Pharm Inc | Leucinamide derivatives suitable as cathepsin cysteine protease inhibitors |
| EP1569954A1 (en) * | 2002-12-05 | 2005-09-07 | Axys Pharmaceuticals, Inc. | Cyanomethyl derivatives as cysteine protease inhibitors |
| WO2005028429A2 (en) * | 2003-09-18 | 2005-03-31 | Axys Pharmaceuticals, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
| PT1855674E (pt) * | 2005-03-02 | 2014-10-08 | Merck Canada Inc | Composição para a inibição de catepsina k |
-
2005
- 2005-11-11 AR ARP050104742A patent/AR055283A1/es not_active Application Discontinuation
- 2005-11-14 MY MYPI20055317A patent/MY137717A/en unknown
- 2005-11-16 TW TW094140285A patent/TWI353244B/zh not_active IP Right Cessation
- 2005-11-17 PE PE2005001349A patent/PE20061054A1/es not_active Application Discontinuation
- 2005-11-18 ES ES05808098T patent/ES2394618T3/es not_active Expired - Lifetime
- 2005-11-18 BR BRPI0518054-6A patent/BRPI0518054A/pt not_active IP Right Cessation
- 2005-11-18 PL PL05808098T patent/PL1817276T3/pl unknown
- 2005-11-18 AU AU2005309267A patent/AU2005309267B2/en not_active Ceased
- 2005-11-18 CN CNA2005800399148A patent/CN101061093A/zh active Pending
- 2005-11-18 US US11/791,250 patent/US20070293578A1/en not_active Abandoned
- 2005-11-18 JP JP2007541606A patent/JP5055488B2/ja not_active Expired - Fee Related
- 2005-11-18 MX MX2007006136A patent/MX2007006136A/es active IP Right Grant
- 2005-11-18 RU RU2007123611/04A patent/RU2399613C2/ru not_active IP Right Cessation
- 2005-11-18 CA CA2589085A patent/CA2589085C/en not_active Expired - Lifetime
- 2005-11-18 CN CN2011102515598A patent/CN102391151A/zh active Pending
- 2005-11-18 US US11/282,536 patent/US7407959B2/en active Active
- 2005-11-18 SI SI200531613T patent/SI1817276T1/sl unknown
- 2005-11-18 EP EP05808098A patent/EP1817276B1/en not_active Expired - Lifetime
- 2005-11-18 KR KR1020077011749A patent/KR20070085435A/ko not_active Abandoned
- 2005-11-18 NZ NZ554872A patent/NZ554872A/en not_active IP Right Cessation
- 2005-11-18 WO PCT/CA2005/001764 patent/WO2006056047A1/en not_active Ceased
- 2005-11-18 DK DK05808098.7T patent/DK1817276T3/da active
- 2005-11-18 PT PT05808098T patent/PT1817276E/pt unknown
-
2007
- 2007-05-02 ZA ZA2007/03530A patent/ZA200703530B/en unknown
- 2007-05-17 IL IL183308A patent/IL183308A/en not_active IP Right Cessation
- 2007-06-22 NO NO20073222A patent/NO339125B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055283A1 (es) | Inhibidores de cisteinproteasa de catepsina | |
| AR036586A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen | |
| AR075139A1 (es) | Compuestos biciclicos para la reduccion de la produccion de beta-amiloide | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| PH12015502192A1 (en) | Novel compounds | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| UA87153C2 (ru) | Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| NO20065178L (no) | Tienopyridinderivater | |
| PE20090435A1 (es) | Inhibidores de tetrahidropiranocromeno de gamma secretasa | |
| PE20212253A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| PE20081530A1 (es) | Nuevos compuestos 617 | |
| AR047972A1 (es) | Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas. | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
| PE20161443A1 (es) | Compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |